Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bioatla Inc (BCAB)

Bioatla Inc (BCAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,141
  • Shares Outstanding, K 1,657
  • Annual Sales, $ 2,000 K
  • Annual Income, $ -59,610 K
  • EBIT $ -61 M
  • EBITDA $ -61 M
  • 60-Month Beta 1.22
  • Price/Sales 3.69
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 0.00% (unch)
  • Historical Volatility 121.04%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 1,150.98% on 08/08/25
  • IV Low 0.00% on 04/13/26
  • Expected Move (DTE 3) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 18
  • Volume Avg (30-Day) 29
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 6,162
  • Open Int (30-Day) 6,235
  • Expected Range 4.98 to 4.98

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-0.32
  • Growth Rate Est. (year over year) +312,287.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.92 +8.93%
on 04/07/26
10.25 -58.34%
on 03/17/26
-3.99 (-48.27%)
since 03/13/26
3-Month
3.92 +8.93%
on 04/07/26
19.25 -77.82%
on 01/23/26
-12.68 (-74.81%)
since 01/14/26
52-Week
3.92 +8.93%
on 04/07/26
71.50 -94.03%
on 11/19/25
-11.49 (-72.91%)
since 04/14/25

Most Recent Stories

More News
BioAtla Announces Share Consolidation

SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ: BCAB or the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic...

BCAB : 4.27 (-0.93%)
BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Initiated a formal process to monetize assets  Implemented a restructuring plan to significantly reduce operating expenses and extend runway SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- BioAtla,...

BCAB : 4.27 (-0.93%)
BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets

SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ: BCAB or the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic...

BCAB : 4.27 (-0.93%)
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)

BioAtla will receive an initial $5 million for general operating and Phase 3 clinical trial expenses to advance Oz-V in 2L+ OPSCC with the remaining $35 million anticipated to close in Q1 2026. BioAtla...

BCAB : 4.27 (-0.93%)
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing

These agreements are designed to be a flexible financing solution to support operations while finalizing a strategic partnership Company is in advanced stages to finalize a strategic transaction with...

BCAB : 4.27 (-0.93%)
BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Company achieved FDA alignment on Phase 3 Oz-V trial for the treatment of 2L+ OPSCC, which will evaluate dual primary endpoints with potential of achieving accelerated approval followed by full approval...

BCAB : 4.27 (-0.93%)
BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas

— Mec-V demonstrates median OS of 21.5 months in patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma compared with approximately 12 months with approved...

BCAB : 4.27 (-0.93%)
BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025

SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics...

BCAB : 4.27 (-0.93%)
BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society

SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics...

BCAB : 4.27 (-0.93%)
BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025

Adverse events (AEs) generally transient and readily manageable; only 2 cases of cytokine release syndrome (CRS) Prolonged tumor control with increasing doses of BA3182; confirmed partial response...

BCAB : 4.27 (-0.93%)

Business Summary

BioAtla Inc. is a clinical-stage biopharmaceutical company. It engages in developing a novel class of antibody-based therapeutics for the treatment of solid tumor cancer. BioAtla Inc. is based in SAN DIEGO.

See More

Key Turning Points

3rd Resistance Point 4.66
2nd Resistance Point 4.56
1st Resistance Point 4.41
Last Price 4.27
1st Support Level 4.16
2nd Support Level 4.06
3rd Support Level 3.91

See More

52-Week High 71.50
Fibonacci 61.8% 45.68
Fibonacci 50% 37.71
Fibonacci 38.2% 29.74
Last Price 4.27
52-Week Low 3.92

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.